A selective small-molecule inhibitor of c-Jun N-terminal kinase 1.


Indiscriminately suppressing total c-Jun N-terminal kinase (JNK) activity is not an appropriate strategy because each JNK appears to have a distinct function in cancer, asthma, diabetes, or Parkinson's disease. Herein, we report that 7-(6-N-phenylaminohexyl)amino-2H-anthra[1,9-cd]pyrazol-6-one (AV-7) inhibited JNK1 activity, but not JNK2 or JNK3. We found… (More)
DOI: 10.1016/j.febslet.2009.06.017


  • Presentations referencing similar topics